



J H M Schellens

Kontakt

J H M Schellens

Publikationen (14)

Meulendijks D, Rozeman E, Cats A, Sikorska K, Jörger M, Deenen M, Beijnen J, Schellens J. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. *Pharmacogenomics J* 2016

Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. *Cancer Chemother Pharmacol* 2015; 75:763-72.

Jörger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F, Cerny T, Schellens J, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatobiliary cancer and hepatic dysfunction. *Cancer Chemother Pharmacol* 2013; 73:113-24.

Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. *Cancer Chemother Pharmacol* 2011; 69:25-33.

Jörger M, deJong D, Burylo A, Burgers J, Baas P, Huitema A, Beijnen J, Schellens J. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non-small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. *Lung Cancer* 2011; 74:310-7.

Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. *Br J Cancer* 2010; 102:673-7.

Jörger M, Huitema A, Huizing M, Willemse P, de Graeff A, Rosing H, Schellens J, Beijnen J, Vermorken J. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. *British journal of clinical pharmacology* 2007; 64:622-33.

Brouwers E, Tibben M, Rosing H, Hillebrand M, Jörger M, Schellens J, Beijnen J. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. *Journal of mass spectrometry : JMS* 2006; 41:1186-94.

Jörger M, Huitema A, Boogerd W, van der Sande J, Schellens J, Beijnen J. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. *Basic & clinical pharmacology & toxicology* 2006; 99:133-40.

Jörger M, Bosch T, Doodeman V, Beijnen J, Smits P, Schellens J. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. *European journal of clinical pharmacology* 2006; 62:681-4.

Jörger M, Huitema A, van den Bongard H, Baas P, Schornagel J, Schellens J, Beijnen J. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. *British journal of clinical pharmacology* 2006; 62:71-80.

Brouwers E, Tibben M, Jörger M, van Tellingen O, Rosing H, Schellens J, Beijnen J. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. *Analytical and bioanalytical chemistry* 2005; 382:1484-90.

Jörger M, Huitema A, Meenhorst P, Schellens J, Beijnen J. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. *Cancer chemotherapy and pharmacology* 2005; 55:488-96.

Jörger M, Schellens J, Beijnen J. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. *Methods and findings in experimental and clinical pharmacology* 2004; 26:531-45.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch